Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

UGT1A1 genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation.

Journal of clinical pharmacology - 1 Apr 2016

Peer Cody J, Goey Andrew K L, Sissung Tristan M, Erlich Sheryl, Lee Min-Jung, Tomita Yusuke, Trepel Jane B, Piekarz Richard, Balasubramaniam Sanjeeve, Bates Susan E, Figg William D

Abstract excerpt

Belinostat is a second-generation zinc-binding histone deacetylase inhibitor that is approved for peripheral T-cell lymphoma and is currently being studied in small cell lung cancer and other advanced carcinomas as a 48-hour continuous intravenous infusion. Belinostat is predominantly metabolized by UGT1A1, which is polymorphic. Preliminary analyses revealed a difference in belinostat clearance based on UGT1A1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Albumins
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Creatinine

Share to Glucuronosyltransferase

Share to Hydroxamic Acids

Share to Kinetics

Share to Pharmacogenetics

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 26637161
DOI: 10.1002/jcph.627
PMCID: PMC6357964

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

UGT1A1 genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation.PMID 26637161Read ↗

Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer.Semantic proximity Read ↗

Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients.Semantic proximity Read ↗

Pharmacogenomics and Histone Deacetylase InhibitorsSemantic proximity Read ↗

Anticancer clinical efficiency and stochastic mechanisms of belinostatSemantic proximity Read ↗

Oncology Drug Dosing in Gilbert Syndrome Associated with UGT1A1: A Summary of the Literature.Semantic proximity Read ↗

Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer.Semantic proximity Read ↗

Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients.Semantic proximity Read ↗

Development of the Weight-Tiered Q3W Regimen of Amivantamab in Combination With Carboplatin-Pemetrexed in EGFR-Mutated Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Pharmacogenomic progress in individualized dosing of key drugs for cancer patients.Semantic proximity Read ↗

Personalized Dose of Adjuvant Imatinib in Patients with Gastrointestinal Stromal Tumors: Results from a Population Pharmacokinetic Analysis.Semantic proximity Read ↗

Population pharmacokinetics and pharmacogenetics of apatinib in adult cancer patients.Semantic proximity Read ↗

A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.